A phase II single-arm study of irinotecan in combination with temozolomide (TEMIRI) in children with newly diagnosed high grade glioma: A joint ITCC and SIOPE-brain tumour study

Journal of Neuro-Oncology

Volumn 113, Issue 1, 2013, Pages 127-134

  Hargrave, Darren ^a   Geoerger, Birgit ^b   Frappaz, Didier ^c   Pietsch, Torsten ^d   Gesner, Lyle ^e   Cisar, Laura ^f   Breazna, Aurora ^f   Dorman, Andrew ^f   Cruz Martinez, Ofelia ^g   Fuster, Jose Luis ^h   Rialland, Xavier ⁱ   Icher, Céline ^j   Leblond, Pierre ^k   Ashley, David ^l   Perilongo, Giorgio ^m   Elliott, Martin ⁿ   English, Martin ^o   Clausen, Niels ^p   Grill, Jacques ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c CENTRE LÉON BÉRARD   (France)

^d UNIVERSITY HOSPITAL BONN   (Germany)

^e SAINT BARNABAS MEDICAL CENTER   (United States)

^f PFIZER INC   (United States)

^g UNIVERSITY OF BARCELONA   (Spain)

^h HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

ⁱ ANGERS UNIVERSITY HOSPITAL   (France)

^j HÔPITAL PELLEGRIN   (France)

^k CENTRE OSCAR LAMBRET   (France)

^l DEAKIN UNIVERSITY   (Australia)

^m UNIVERSITY OF PADOVA   (Italy)

ⁿ LEEDS GENERAL INFIRMARY   (United Kingdom)

^o BIRMINGHAM CHILDREN S HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^p AARHUS UNIVERSITY HOSPITAL   (Denmark)

more..

Author keywords

Adolescents; Anaplastic astrocytoma; Anaplastic oligodendroglioma; Child; Glioblastoma; High grade glioma; Irinotecan; Malignant glioma; Neoadjuvant chemotherapy; Temozolomide

Indexed keywords

IRINOTECAN; TEMOZOLOMIDE;

ABDOMINAL PAIN; ADOLESCENT; ARTICLE; ASTHENIA; ASTROCYTOMA; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; FATIGUE; FEMALE; GLIOBLASTOMA; GLIOMA; GLIOSARCOMA; HISTOPATHOLOGY; HUMAN; HYPERHIDROSIS; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; SCHOOL CHILD; TUMOR LOCALIZATION; UNSPECIFIED SIDE EFFECT; VOMITING;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CAMPTOTHECIN; CHILD; CHILD, PRESCHOOL; DACARBAZINE; FEMALE; GLIOMA; HUMANS; MALE; NEOPLASM GRADING; TREATMENT OUTCOME;

EID: 84876895738     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-013-1098-2     Document Type: Article

References (56)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) (2007) WHO classification of tumours of the central nervous system, 4th edn. IARC Press, Lyon
2. Hargrave D (2009) Paediatric high and low grade glioma: the impact of tumour biology on current and future therapy. Br J Neurosurg 23(4):351-363
3. Cohen KJ, Pollack IF, Zhou T et al (2011) Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group. Neuro Oncol 13(3):317-323
4. Sposto R, Ertel IJ, Jenkin RD et al (1989) The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial. A report from the Childrens Cancer Study Group. J Neurooncol 7(2):165-177
5. Finlay JL, Boyett JM, Yates AJ et al (1995) Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. Childrens Cancer Group. J Clin Oncol 13(1):112-123
6. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987-996
7. Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459-466
8. Gerson SL (2004) MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 4(4):296-307
9. Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997-1003
10. Lashford LS, Thiesse P, Jouvet A et al (2002) Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. J Clin Oncol 20(24):4684-4691
11. Brada M, Hoang-Xuan K, Rampling R et al (2001) Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 12(2):259-266
12. Nicholson HS, Kretschmar CS, Krailo M et al (2007) Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer 110(7):1542-1550
13. Ruggiero A, Cefalo G, Garre ML et al (2006) Phase II trial of temozolomide in children with recurrent high-grade glioma. J Neurooncol 77(1):89-94
14. Broniscer A, Chintagumpala M, Fouladi M et al (2006) Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children. J Neurooncol 76(3):313-319
15. Balana C, Lopez-Pousa A, Berrocal A et al (2004) Phase II study of temozolomide and cisplatin as primary treatment prior to radiotherapy in newly diagnosed glioblastoma multiforme patients with measurable disease. A study of the Spanish Medical Neuro-Oncology Group (GENOM). J Neurooncol 70(3):359-369
16. Brandes AA, Basso U, Reni M et al (2004) First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia. J Clin Oncol 22(9):1598-1604
17. Silvani A, Eoli M, Salmaggi A et al (2004) Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients. J Neurooncol 66(1-2):203-208
18. 6-alkylguanine-DNA alkyltransferase study of cisplatin combined with temozolomide in paediatric solid malignancies. Br J Cancer 93(5):529-537
19. Zustovich F, Lombardi G, Della PA, Rotilio A, Scienza R, Pastorelli D (2009) A phase II study of cisplatin and temozolomide in heavily pre-treated patients with temozolomide-refractory high-grade malignant glioma. Anticancer Res 29(10):4275-4279
20. Blaney S, Berg SL, Pratt C et al (2001) A phase I study of irinotecan in pediatric patients: a pediatric oncology group study. Clin Cancer Res 7(1):32-37
21. Turner CD, Gururangan S, Eastwood J et al (2002) Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience. Neuro Oncol 4(2):102-108
22. Crews KR, Stewart CF, Jones-Wallace D et al (2002) Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy. Clin Cancer Res 8(7):2202-2209
23. Vassal G, Doz F, Frappaz D et al (2003) A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors. J Clin Oncol 21(20):3844-3852
24. Gajjar A, Chintagumpala MM, Bowers DC, Jones-Wallace D, Stewart CF, Crews KR (2003) Effect of intrapatient dosage escalation of irinotecan on its pharmacokinetics in pediatric patients who have high-grade gliomas and receive enzyme-inducing anticonvulsant therapy. Cancer 97(9 Suppl):2374-2380
25. 6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models. Clin Cancer Res 6(10):4110-4118
26. Coggins CA, Elion GB, Houghton PJ et al (1998) Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents. Cancer Chemother Pharmacol 41(6):485-490
27. Fallik D, Borrini F, Boige V et al (2003) Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res 63:5738-5744
28. Okamoto R, Takano H, Okamura T et al (2002) o(6)-methylguanine-DNA methyltransferase (MGMT) as a determinant of resistance to camptothecin derivatives. Jpn J Cancer Res 93:93-102
29. 6-methylguanine. Cancer Res 61:53-58
30. Reardon DA, Quinn JA, Rich JN et al (2005) Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. Cancer 104(7):1478-1486
31. Gruber ML, Buster WP (2004) Temozolomide in combination with irinotecan for treatment of recurrent malignant glioma. Am J Clin Oncol 27(1):33-38
32. Quinn JA, Jiang SX, Reardon DA et al (2009) Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy. J Neurooncol 95(3):393-400
33. Fountzilas G, Karkavelas G, Kalogera-Fountzila A et al (2006) Post-operative combined radiation and chemotherapy with temozolomide and irinotecan in patients with high-grade astrocytic tumors. A phase II study with biomarker evaluation. Anticancer Res 26(6):4675-4686
34. Wagner LM, Crews KR, Iacono LC et al (2004) Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors. Clin Cancer Res 10(3):840-848
35. Kushner BH, Kramer K, Modak S, Cheung NK (2006) Irinotecan plus temozolomide for relapsed or refractory neuroblastoma. J Clin Oncol 24(33):5271-5276
36. Wagner LM, McAllister N, Goldsby RE et al (2007) Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer 48(2):132-139
37. Casey DA, Wexler LH, Merchant MS et al (2009) Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience. Pediatr Blood Cancer 53(6):1029-1034
38. McNall-Knapp RY, Williams CN, Reeves EN, Heideman RL, Meyer WH (2010) Extended phase I evaluation of vincristine, irinotecan, temozolomide, and antibiotic in children with refractory solid tumors. Pediatr Blood Cancer 54(7):909-915
39. Wagner LM, Perentesis JP, Reid JM et al (2010) Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study. Pediatr Blood Cancer 54(4):538-545
40. Bagatell R, London WB, Wagner LM et al (2011) Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study. J Clin Oncol 29(2):208-213
41. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47(1):207-214
42. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10(1):1-10
43. Wagner LM, Villablanca JG, Stewart CF et al (2009) Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study. J Clin Oncol 27(8):1290-1296
44. Pollack IF, Boyett JM, Yates AJ et al (2003) The influence of central review on outcome associations in childhood malignant gliomas: results from the CCG-945 experience. Neuro Oncol 5(3):197-207
45. Chastagner P, Kalifa C, Doz F et al (2007) Outcome of children treated with preradiation chemotherapy for a high-grade glioma: results of a French Society of Pediatric Oncology (SFOP) Pilot Study. Pediatr Blood Cancer 49(6):803-807
46. van den Bent MJ, Vogelbaum MA, Wen PY, Macdonald DR, Chang SM (2009) End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria. J Clin Oncol 27(18):2905-2908
47. Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28(11):1963-1972
48. Verschuur AC, Grill J, Lelouch-Tubiana A, Couanet D, Kalifa C, Vassal G (2004) Temozolomide in paediatric high-grade glioma: a key for combination therapy? Br J Cancer 91(3):425-429
49. Estlin EJ, Lashford L, Ablett S et al (1998) Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children's Cancer Study Group. Br J Cancer 78(5):652-661
50. Gaspar N, Marshall L, Perryman L et al (2010) MGMT-independent temozolomide resistance in paediatric glioblastoma cells associated with a PI3-kinase-mediated HOX/stem cell gene signature. Cancer Res 70(22):9243-9252
51. Bax DA, Mackay A, Little SE et al (2010) A distinct spectrum of copy number aberrations in paediatric high-grade gliomas. Clin Cancer Res 16(13):3368-3377
52. Paugh BS, Qu C, Jones C et al (2010) Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol 28(18):3061-3068
53. Wolff JE, Gnekow AK, Kortmann RD et al (2002) Preradiation chemotherapy for pediatric patients with high-grade glioma. Cancer 94(1):264-271
54. Finlay JL, Geyer JR, Turski PA et al (1994) Pre-irradiation chemotherapy in children with high-grade astrocytoma: tumor response to two cycles of the '8-drugs-in-1-day' regimen. A Childrens Cancer Group study, CCG-945. J Neurooncol 21(3):255-265
55. Brada M, Ashley S, Dowe A et al (2005) Neoadjuvant phase II multicentre study of new agents in patients with malignant glioma after minimal surgery. Report of a cohort of 187 patients treated with temozolomide. Ann Oncol 16(6):942-949
56. Stupp R, Dietrich PY, Ostermann KS et al (2002) Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20(5):1375-1382